Abstract
Correction: Monitoring of Regulatory T Cell Frequencies and Expression of CTLA-4 on T Cells, before and after DC Vaccination, Can Predict Survival in GBM Patients
Highlights
Glioblastoma is one of the most lethal of human cancers, with very few long-term survivors and no definitive cures for this disease
The change in regulatory T cell (CD3+CD4+CD25+CD127low) frequency in peripheral blood lymphocyte (PBL) was significantly associated with survival (p = 0.0228; hazard ratio = 3.623) after dendritic cells (DC) vaccination
Our results suggest that monitoring the change in regulatory T cell frequencies and dynamic expression of the negative co-stimulatory molecules on peripheral blood T cells, before and after DC vaccination, may predict survival
Summary
Glioblastoma is one of the most lethal of human cancers, with very few long-term survivors and no definitive cures for this disease These tumors invade and infiltrate the surrounding brain, making complete surgical excision impossible. Immunotherapy is theoretically appealing because it offers the potential for a high degree of tumor-specificity, while sparing normal brain structures [10]. One such approach uses professional antigen-presenting cells, known as dendritic cells (DC), co-cultured with autologous tumor lysate or glioma-associated antigens to target these tumors immunologically. Initial studies of DC-based vaccine therapy for malignant gliomas have shown acceptable safety and toxicity profiles [11,12,13,14,15,16,17,18,19,20,21,22], and multi-center randomized Phase II and III studies are currently underway
Sign-in/Register to view highlights & summary 
Published Version (
Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call